|Bid||56.51 x 0|
|Ask||56.53 x 0|
|Day's Range||56.06 - 57.50|
|52 Week Range||31.81 - 76.68|
|Beta (3Y Monthly)||5.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.00|
Martha Stewart commands a massive audience when she cooks, decorates and gardens. But the 77-year-old food and lifestyle guru has been tight-lipped about her personal use of cannabis.
On June 19, Canopy Growth (WEED) (CGC) and CURE Pharmaceutical announced a partnership to create a new CBD-based oral delivery thin film. The oral thins will be available for distribution globally.
Learn why young investors should be willing to look past the short-term risks of their investments in favour of their long-term potential and how stocks like Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) might end up looking like unbelievable bargains 40 years from now.
Canopy Growth Corp (TSX:WEED)(NYSE:CGC) will release its fourth-quarter results tomorrow. Here's what to look out for.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.
Canadian cannabis company Canopy Growth is scheduled to report fiscal fourth-quarter 2019 earnings on Thursday after the market closes.
Canopy Growth is making progress in the Australian market through its Spectrum Therapeutics brand, which caters to the demand for medical cannabis products. According to the company, the number of medical patients in the country has increased ten times in the last year.
New York has been on the fence about legalizing marijuana. In a series of tweets, New York City Mayor Bill De Blasio expressed strong support for legalizing cannabis the “RIGHT way.”
On June 18, Canopy Growth (WEED) (CGC) announced another international development: it has entered into an agreement with Procaps in Colombia. According to Canopy Growth, Procaps is active across the world, exporting its products to over 50 international markets.
On June 20, Canopy Growth (WEED) (CGC) is expected to report sales of 91.1 million Canadian dollars and a gross income of 24.4 million Canadian dollars. The company's margins are expected to compress.
As it shifts its focus to the U.S. market, Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is going to need to run a much tighter ship in Canada.
On June 20, Canopy Growth (WEED) (CGC) is scheduled to announce its fourth-quarter and fiscal 2019 earnings after the market closes. The company's guidance will likely set the tone for the cannabis industry's near-term expectations.
Although marijuana stocks like Canopy Growth Corp (TSX:WEED)(NYSE:CGC) have been rising for a long time, it may not be too late to earn some gains from them.
The sentiment towards the cannabis sector weakened further last week, as major industry players ended in the negative territory. HEXO (HEXO), which released disappointing earnings on June 12, was one of the key reasons for the extension of the weakness in the sector last week.
Which stock wins in a battle between the biggest cannabis producer by market cap and the biggest supplier to the cannabis industry?
Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is the top Canadian pot company to watch as the United States creeps closer to broader legalization.
Canopy Growth's brands, technology and know-how is anticipated to provide Acreage with a significant advantage in an increasingly competitive U.S. market and fuel Acreage's growth. Acreage shareholders will benefit from Acreage's ability to achieve its growth strategy with an anticipated reduced cost of capital based on Canopy Growth affiliation. Canopy Growth shareholders will benefit from accelerated and turnkey access to the U.S. cannabis market upon the closing of the Transaction.
Shares of CBD company CV Sciences jumped 10% on a deal with retailer Kroger to sell its oils in nearly 1,000 stores.
Here's what I would be focused on as marijuana king Canopy Growth Corp (TSX:WEED)(NYSE:CGC) reports earnings next week.